Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Cicletanine→

Cicletanine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
89943-82-8
Molecular formula
C14H12ClNO2
Molecular weight
261.7 g/mol
Drug class
Low-ceiling diuretic and antihypertensive agent (ATC C03BX03)
Mechanism of action
Produces salidiuretic activity through an active sulfoconjugated metabolite that inhibits a sodium-dependent chloride/bicarbonate exchanger in the distal convoluted tubule. Vasodilator effects are complex and may involve prostaglandin synthesis, cyclic-GMP phosphodiesterase inhibition, calcium-channel effects and potassium-channel opening; the relative clinical contributions are not fully established.
Indications / reported uses
  • Treatment of arterial hypertension in countries where cicletanine is authorised; antihypertensive use is supported by historical clinical and pharmacological literature, while current market availability is limited

Sources: PubMed — Cicletanine: new insights into its pharmacological actions · PubMed — General pharmacology of cicletanine · WHO ATC/DDD Index — C03BX03 · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Cicletanine Environmental Risk Assessment (ERA) (the Cicletanine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.